Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions.
| CAS Number | 1001080-50-7 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[4] Peiran Yang, et al. N Engl J Med. Sotatercept for Pulmonary Arterial Hypertension
| Related TGF-beta/Smad Products |
|---|
| A 83-01 sodium
A 83-01 sodium is a potent inhibitor of TGF-β type I receptors ALK5, ALK4, and ALK7, inhibiting ALK5, ALK4, and ALK7-induced transcription with IC50 values of 12 nM, 45 nM, and 7.5 nM, respectively. |
| Myristoyl tetrapeptide-12
Myristoyl tetrapeptide-12 directly activates SMAD2 and induces the linking of SMAD3 with DNA. |
| H-Leu-Ser-Lys-Leu-OH
H-Leu-Ser-Lys-Leu-OH (LSYL) is a latency-associated peptide at the amino terminus of LAP, with inhibitory effect on TGF-β1 activation. |
| SY-LB-35
SY-LB-35 is a potent bone morphogenetic protein (BMP) receptor agonist. |
| DT-6
DT-6 is an effective TGF-β1 inhibitor. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
